Stock listing
NYSE American:IGC IGC Pharma, Inc. Stock
Home listing (NYSE American) of IGC Pharma, Inc.
Follow IGC Pharma, Inc. into a list and get an email when it puts out news.
Share price · AMEX:IGC
$0.168 USD -0.027 (-13.7%)
Close on Nov 20, 2026
- Day range
- $0.168 – $0.186 USDNov 20, 2026
- Volume
- 500,330 sharesNov 20, 2026
- Market cap
- $19.60M USDAt the close on Nov 20, 2026 · price × 116.7M shares outstanding
- 52-week range
- $0.080 – $0.360 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $167,876 USDMedian day 507,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:IGC · Home | $0.168 USD | -0.027 (-13.7%) | 500,330 | $0.183 | $0.186 | $0.168 | $0.195 | Close on Nov 20, 2026 |
| Frankfurt:IGS1 | €0.164 EUR | -0.010 (-5.7%) | — | €0.164 | €0.164 | €0.164 | €0.174 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:IGC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.168 | -0.027 | -13.7% | $0.183 | $0.186 | $0.168 | 500,330 | |
| $0.195 | +0.007 | +3.6% | $0.190 | $0.200 | $0.188 | 678,535 | |
| $0.188 | +0.013 | +7.4% | $0.177 | $0.189 | $0.175 | 350,049 | |
| $0.175 | -0.001 | -0.6% | $0.175 | $0.184 | $0.175 | 427,758 | |
| $0.176 | -0.009 | -4.6% | $0.189 | $0.189 | $0.168 | 507,946 | |
| $0.185 | -0.014 | -7.2% | $0.190 | $0.190 | $0.183 | 364,001 | |
| $0.199 | +0.003 | +1.5% | $0.195 | $0.200 | $0.191 | 186,154 | |
| $0.196 | -0.008 | -4.1% | $0.200 | $0.205 | $0.191 | 203,860 | |
| $0.204 | +0.004 | +2.2% | $0.194 | $0.206 | $0.193 | 391,385 | |
| $0.200 | +0.011 | +5.8% | $0.191 | $0.201 | $0.181 | 589,981 | |
| $0.189 | -0.006 | -3.1% | $0.197 | $0.197 | $0.179 | 814,279 | |
| $0.195 | +0.009 | +4.8% | $0.191 | $0.195 | $0.188 | 323,169 | |
| $0.186 | -0.007 | -3.6% | $0.193 | $0.200 | $0.185 | 350,501 | |
| $0.193 | +0.008 | +4.3% | $0.200 | $0.200 | $0.185 | 397,910 | |
| $0.185 | -0.014 | -7.1% | $0.191 | $0.197 | $0.181 | 504,332 | |
| $0.199 | -0.040 | -16.5% | $0.245 | $0.245 | $0.080 | 2,007,404 | |
| $0.239 | -0.009 | -3.7% | $0.250 | $0.251 | $0.238 | 509,508 | |
| $0.248 | -0.002 | -0.8% | $0.246 | $0.250 | $0.245 | 118,314 | |
| $0.250 | 0.000 | 0.0% | $0.245 | $0.253 | $0.243 | 323,314 | |
| $0.250 | 0.000 | 0.0% | $0.250 | $0.250 | $0.240 | 124,200 | |
| $0.250 | +0.010 | +4.2% | $0.250 | $0.250 | $0.240 | 175,200 | |
| $0.240 | -0.010 | -4.0% | $0.250 | $0.250 | $0.240 | 364,800 | |
| $0.250 | +0.010 | +4.2% | $0.240 | $0.250 | $0.240 | 446,100 | |
| $0.240 | -0.010 | -4.0% | $0.250 | $0.270 | $0.240 | 541,100 | |
| $0.250 | 0.000 | 0.0% | $0.260 | $0.260 | $0.240 | 406,000 | |
| $0.250 | 0.000 | 0.0% | $0.260 | $0.260 | $0.250 | 781,400 | |
| $0.250 | -0.020 | -7.4% | $0.260 | $0.260 | $0.250 | 946,100 | |
| $0.270 | -0.010 | -3.6% | $0.270 | $0.270 | $0.260 | 422,100 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.290 | $0.270 | 573,000 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.280 | $0.280 | 232,200 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.290 | $0.280 | 626,400 | |
| $0.280 | 0.000 | 0.0% | $0.290 | $0.290 | $0.280 | 306,800 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.290 | $0.280 | 1,111,900 | |
| $0.280 | +0.010 | +3.7% | $0.280 | $0.290 | $0.270 | 1,768,500 | |
| $0.270 | 0.000 | 0.0% | $0.280 | $0.280 | $0.270 | 630,600 | |
| $0.270 | 0.000 | 0.0% | $0.270 | $0.280 | $0.270 | 449,900 | |
| $0.270 | 0.000 | 0.0% | $0.270 | $0.280 | $0.270 | 808,900 | |
| $0.270 | 0.000 | 0.0% | $0.280 | $0.280 | $0.270 | 523,700 | |
| $0.270 | -0.010 | -3.6% | $0.290 | $0.300 | $0.270 | 1,102,300 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.290 | $0.280 | 681,600 | |
| $0.280 | -0.010 | -3.4% | $0.280 | $0.290 | $0.280 | 332,800 | |
| $0.290 | +0.010 | +3.6% | $0.290 | $0.290 | $0.280 | 540,500 | |
| $0.280 | +0.010 | +3.7% | $0.270 | $0.280 | $0.270 | 609,700 | |
| $0.270 | -0.020 | -6.9% | $0.290 | $0.290 | $0.270 | 507,100 | |
| $0.290 | +0.020 | +7.4% | $0.270 | $0.290 | $0.270 | 811,600 | |
| $0.270 | 0.000 | 0.0% | $0.280 | $0.290 | $0.270 | 713,500 | |
| $0.270 | 0.000 | 0.0% | $0.270 | $0.280 | $0.270 | 473,500 | |
| $0.270 | -0.010 | -3.6% | $0.270 | $0.280 | $0.270 | 501,000 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.280 | $0.270 | 819,500 | |
| $0.280 | 0.000 | 0.0% | $0.290 | $0.290 | $0.280 | 413,600 | |
| $0.280 | 0.000 | 0.0% | $0.290 | $0.290 | $0.280 | 615,400 | |
| $0.280 | -0.010 | -3.4% | $0.300 | $0.300 | $0.280 | 344,900 | |
| $0.290 | -0.010 | -3.3% | $0.300 | $0.300 | $0.290 | 571,100 | |
| $0.300 | 0.000 | 0.0% | $0.300 | $0.300 | $0.300 | 372,600 | |
| $0.300 | 0.000 | 0.0% | $0.300 | $0.300 | $0.300 | 345,600 | |
| $0.300 | 0.000 | 0.0% | $0.300 | $0.300 | $0.300 | 457,000 | |
| $0.300 | 0.000 | 0.0% | $0.300 | $0.310 | $0.300 | 774,700 | |
| $0.300 | -0.010 | -3.2% | $0.310 | $0.320 | $0.290 | 619,100 | |
| $0.310 | -0.020 | -6.1% | $0.330 | $0.340 | $0.310 | 926,100 | |
| $0.330 | +0.020 | +6.5% | $0.310 | $0.340 | $0.310 | 3,598,300 | |
| $0.310 | +0.005 | +1.8% | $0.310 | $0.310 | $0.300 | 453,000 | |
| $0.305 | +0.004 | +1.3% | $0.301 | $0.308 | $0.300 | 387,273 | |
| $0.301 | -0.009 | -3.0% | $0.310 | $0.310 | $0.300 | 916,488 | |
| $0.310 | +0.030 | +10.7% | $0.290 | $0.310 | $0.280 | 1,867,400 | |
| $0.280 | -0.010 | -3.4% | $0.290 | $0.290 | $0.270 | 603,600 |
Splits
1 split · AMEX:IGC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- NYSE American:IGC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
Latest deck · Jul 14, 2026
Investor Presentation (July 2026)
Investor deck · 25 slides
Latest news
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
Nov 18, 2026
Closed $0.195 (+3.6%) on Nov 18, 2026
IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 9, 2026
Closed $0.204 (+2.2%) on Nov 9, 2026
IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears
Nov 5, 2026
Closed $0.189 (-3.1%) on Nov 5, 2026
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment
Oct 13, 2026
Closed $0.27 (-3.6%) on Oct 13, 2026
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
Sep 28, 2026
Closed $0.27 (-3.6%) on Sep 28, 2026
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
Aug 17, 2026
Closed $0.28 (-6.7%) on Aug 17, 2026
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
Aug 11, 2026
Closed $0.28 (+3.7%) on Aug 11, 2026
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
Jul 29, 2026
Closed $0.24 (-7.3%) on Jul 29, 2026
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
Jul 7, 2026
Closed $0.28 (0.0%) on Jul 7, 2026
IGC Pharma (NYSE: IGC) CEO and CFO Acquire More Than 4.2 Million Shares
Jul 2, 2026
Closed $0.28 (+3.7%) on Jul 2, 2026
IGC Pharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 39 in the last 12 months · 67 in all · newest Nov 18, 2026 · oldest 2025
- Decks
- 14 decks · latest Jul 14, 2026
Where IGC Pharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:IGC · Home listing · This page | NYSE American | United States | USD |
| gettex:IGS1 | gettex | Germany | EUR |
| LS Exchange:A1T87A | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1T87A | Lang & Schwarz | Germany | EUR |
| BOATS:IGC | BOATS | United States | USD |
| Dusseldorf:IGS1 | Dusseldorf | Germany | EUR |
| Frankfurt:IGS1 | Frankfurt | Germany | EUR |
| Munich:IGS1 | Munich | Germany | EUR |
| Stuttgart:IGS1 | Stuttgart | Germany | EUR |
| Tradegate:IGS1 | Tradegate | Germany | EUR |
Valuation
Price/book 3.0× against a median of 0.6×: 7th lowest of 8 Biotechnology companies shown. balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $19.19M USD
- P/E
- Not reported
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 3.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.09
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| IGC Pharma, Inc. · AMEX:IGC | US$19.60M | US$19.19M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.09 |
| ZYUS Life Sciences Corporation · TSXV:ZYUS | US$20.92M | US$25.65M | n/a | 98.4× | n/a | n/a | n/a | n/a | -0.02 |
| Xbrane Biopharma AB · OMXSTO:XBRANE | US$20.86M | US$23.45M | n/a | 1.9× | n/a | 0.4× | −49.0% | 0.1× | n/a |
| Vivoryon Therapeutics N.V. · EURONEXT:VVY | US$20.48M | US$17.77M | n/a | n/a | n/a | 11.9× | n/a | 0.1× | n/a |
| Evaxion A/S · NASDAQ:EVAX | US$20.30M | US$13.40M | n/a | 1.8× | n/a | 2.1× | −115.1% | 0.8× | 0.78 |
| Aardvark Therapeutics, Inc. · NASDAQ:AARD | US$20.20M | −US$39.58M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 3.28 |
| GenSight Biologics SA · EURONEXT:SIGHT | US$20.19M | US$32.44M | n/a | 29,573× | n/a | n/a | n/a | n/a | n/a |
| TransCode Therapeutics, Inc. · NASDAQ:RNAZ | US$20.07M | US$15.44M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.03 |
| Adicet Bio, Inc. · NASDAQ:ACET | US$20.03M | US$5.02M | n/a | n/a | n/a | 0.2× | n/a | 0.1× | 2.02 |
| Provectus Biopharmaceuticals, Inc. · OTC:PVCT | US$19.12M | US$18.94M | n/a | n/a | n/a | n/a | n/a | n/a | -0.21 |
| LeonaBio, Inc. · NASDAQ:LONA | US$19.03M | −US$12.82M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.04 |
| Median of the others | US$20.19M | US$16.60M | 50.1× | 0.6× | −82.1% | 0.1× | 1.03 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.10 · 1 analyst
- Revenue, year to Dec 2026
- 958K · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Ram Mukunda | CEO & Director |
| Andres Sanchez | / Investor Relations |
| Claudia Grimaldi | VP, CCO, PFO, & Director |
| Benysh Qureshi | Director of Operations |
| Jose Ramos | Communications Manager |
Board
| Director | Role |
|---|---|
| Richard Prins | Chairman |
| Claudia Grimaldi | VP, CCO, PFO, & Director |
| Jim Moran | Director |
| Ram Mukunda | CEO & Director |
| Terry Lierman | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2027 | Nov 6, 2026 · After close | +2.2% |
| Q1 2027 | Aug 14, 2026 · After close | −6.7% |
| Q4 2026 | May 15, 2026 · After close | 0.0% |
| Quarter to Dec 31, 2025 | Feb 18, 2026 | +1.6% |
| Q2 2026 | Nov 14, 2025 · After close | −5.6% |
| Q1 2026 | Aug 5, 2025 · After close | −2.4% |
| Q4 2025 | Jun 27, 2025 · After close | 0.0% |
| Q3 2025 | Feb 14, 2025 · After close | 0.0% |
| Q2 2025 | Nov 12, 2024 · After close | −2.6% |
| Q1 2025 | Aug 7, 2024 · After close | 0.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | Jun 24, 2024 · After close | −8.5% |
| Q3 2024 | Feb 14, 2024 · After close | 0.0% |
| Q2 2024 | Nov 9, 2023 · After close | 0.0% |
| Q1 2024 | Aug 10, 2023 · After close | +2.9% |
| Q4 2023 | Jun 30, 2023 · After close | +3.2% |
| Q3 2023 | Feb 14, 2023 · After close | 0.0% |
| Q2 2023 | Nov 1, 2022 · After close | −6.5% |
| Q1 2023 | Aug 5, 2022 · After close | +5.5% |
| Q4 2022 | Jun 22, 2022 · After close | −3.2% |
| Q3 2022 | Feb 10, 2022 · After close | −6.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 25 slides | Jul 14, 2026 |
| Investor Presentation (June 2025) | Investor deck | 50 slides | Jun 17, 2025 |
| FY2025 Earnings Presentation | Earnings | 20 slides | June 2025 |
| Investor Presentation (April 2025) | Investor deck | 28 slides | April 2025 |
| Investor Presentation (February 2024) | Investor deck | 41 slides | February 2024 |
| Investor Presentation (January 2024) | Investor deck | 29 slides | January 2024 |
| Investor Presentation (January 2024) | Investor deck | 29 slides | January 2024 |
| Investor Presentation (August 2023) | Investor deck | 36 slides | Aug 2, 2023 |
| Investor Presentation (February 2023) | Investor deck | 25 slides | Feb 23, 2023 |
| Investor Presentation (February 2023) | Investor deck | 25 slides | February 2023 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2022) | Investor deck | 25 slides | December 2022 |
| India Globalization Capital — Investor Presentation (February 2014) | Investor deck | 14 slides | Feb 6, 2014 |
| India Globalization Capital — Investor Presentation (June 2008) | Investor deck | 8 slides | Jun 4, 2008 |
| India Globalization Capital — Merger or Acquisition (January 2008) | Merger or acquisition | 28 slides | Jan 29, 2008 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of shares of common stock Announced: about US$234,000 · US$0.3 a share Use of proceeds: Working capital and general corporate purposes, including continued funding of the Phase 2 clinical program for IGC-AD1 | Jan 5, 2026 |
| Private placements and at-the-market offering Closed: US$3.5M raised | Aug 19, 2025 |
| Private placement of common shares Announced: about US$475,000 Buyers: Frank Zaccanelli; Robert K. Coughlin; Joseph H. Mangan Use of proceeds: General corporate purposes and advancing the CALMA Phase 2 clinical trial on agitation in Alzheimer's disease | Apr 24, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as India Globalization Capital, Inc., a blank check company (SPAC). Final prospectus filed on Mar 3, 2006.
- Units offered
- 9,830,000 units
- Underwriters' option
- Up to 1,474,500 more units
- Listing
- IGC.U
- Underwriters
- Ferris, Baker Watts Incorporated, Ladenburg Thalmann & Co. Inc., First Albany Capital, Merriman Curhan Ford & Co., SOCIETE GENERALE · In the order on the cover
- Units delivered
- On or about Mar 8, 2006
Steps
| Step | When |
|---|---|
| Filed publicly | May 13, 2005 |
| Amended 7 times | Newest Mar 2, 2006 |
| Shares registered with an exchange | Mar 8, 2006 |
| Final prospectus, with the price | Mar 3, 2006 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 8, 2006 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 8, 2006 |
| 424B4 · Prospectus | Mar 7, 2006 |
| CORRESP · Letter to the SEC | Mar 6, 2006 |
| CORRESP · Letter to the SEC | Mar 6, 2006 |
| 424B3 · Prospectus | Mar 3, 2006 |
| CORRESP · Letter to the SEC | Mar 2, 2006 |
| CORRESP · Letter to the SEC | Mar 2, 2006 |
| CORRESP · Letter to the SEC | Mar 2, 2006 |
| S-1/A · Registration statement, amended | Mar 2, 2006 |
All 26 filings
| Filing | Filed |
|---|---|
| 8-A12G/A · Registration of a class of shares, amended | Feb 27, 2006 |
| UPLOAD · Letter from the SEC | Feb 24, 2006 |
| CORRESP · Letter to the SEC | Feb 14, 2006 |
| S-1/A · Registration statement, amended | Feb 14, 2006 |
| UPLOAD · Letter from the SEC | Nov 17, 2005 |
| S-1/A · Registration statement, amended | Nov 2, 2005 |
| UPLOAD · Letter from the SEC | Sep 15, 2005 |
| 8-A12G · Registration of a class of shares | Sep 6, 2005 |
| S-1/A · Registration statement, amended | Aug 19, 2005 |
| S-1/A · Registration statement, amended | Aug 12, 2005 |
| UPLOAD · Letter from the SEC | Aug 2, 2005 |
| CORRESP · Letter to the SEC | Jul 20, 2005 |
| S-1/A · Registration statement, amended | Jul 19, 2005 |
| S-1/A · Registration statement, amended | Jul 11, 2005 |
| UPLOAD · Letter from the SEC | Jun 24, 2005 |
| S-1 · Registration statement | May 13, 2005 |
Open IPO · From the cover of the final prospectus (424B3) filed Mar 3, 2006
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.27M | 1.34M | 911.0K | 397.0K | 898.0K | 4.07M | 5.12M | 2.19M | 580.4K | 6.37M |
| Cost of revenue | 652.0K | 612.0K | 469.0K | 203.0K | 785.0K | 3.96M | 4.98M | 2.11M | 362.1K | 5.52M |
| Gross profit | 619.0K | 733.0K | 442.0K | 194.0K | 113.0K | 115.0K | 132.0K | 82.0K | 218.2K | 843.3K |
| Research and development | 3.65M | 3.77M | 3.46M | 2.33M | 929.0K | 1.01M | 1.26M | 137.0K | ||
| Selling, general and administrative | 4.41M | 6.76M | 8.55M | 13.3M | 7.91M | 5.97M | 3.52M | 1.73M | 2.27M | 2.70M |
| Operating income | -7.45M | -9.80M | -11.6M | -15.4M | -8.72M | -6.86M | -4.64M | -1.79M | -2.05M | -2.91M |
| Depreciation and amortization | 618.0K | 637.0K | 657.0K | 651.0K | 478.0K | 144.0K | 59.0K | 19.0K | 396.3K | 728.7K |
| EBITDA | -6.83M | -9.16M | -10.9M | -14.8M | -8.25M | -6.72M | -4.58M | -1.77M | -1.66M | -2.18M |
| Interest expense | 5.00K | 5.00K | 5.00K | 5.00K | 3.00K | 30.7K | 223.5K | 213.9K | ||
| Income before tax | -7.12M | -13.0M | -11.5M | -15.0M | -8.81M | -7.32M | -4.09M | -1.79M | -1.84M | -2.83M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 2.00K | 0 | 14.4K | 579 |
| Net income | -7.12M | -13.0M | -11.5M | -15.0M | -8.81M | -7.32M | -4.10M | -1.79M | -1.87M | -2.81M |
| Earnings per share, basic | -0.09 | -0.22 | -0.22 | -0.29 | -0.21 | -0.19 | -0.13 | -0.06 | -0.07 | -0.17 |
| Earnings per share, diluted | -0.09 | -0.22 | -0.21 | -0.19 | -0.13 | -0.06 | -0.07 | -0.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 405.0K | 1.20M | 3.20M | 10.5M | 14.5M | 7.26M | 25.6M | 1.66M | 538.0K | 1.49M |
| Short-term investments | 0 | 0 | 154.0K | 0 | 80.0K | 0 | 0 | 148.0K | 1.88M | 0 |
| Receivables | 34.0K | 39.0K | 107.0K | 125.0K | 175.0K | 133.0K | 84.0K | 558.0K | 752.9K | 962.7K |
| Inventory | 1.36M | 1.54M | 2.65M | 3.55M | 5.48M | 4.25M | 248.0K | 486.0K | 0 | 162.1K |
| Current assets | 2.90M | 3.71M | 6.47M | 15.1M | 23.5M | 17.8M | 26.7M | 3.21M | 3.58M | 3.84M |
| Property, plant and equipment | 3.22M | 3.69M | 8.21M | 9.42M | 10.8M | 9.78M | 5.89M | 6.24M | 953.9K | 7.07M |
| Goodwill | 0 | 198.2K | 1.18M | |||||||
| Total assets | 8.75M | 9.90M | 17.2M | 26.8M | 35.9M | 29.0M | 34.5M | 10.9M | 11.3M | 18.9M |
| Accounts payable | 883.0K | 773.0K | 530.0K | 981.0K | 476.0K | 762.0K | 319.0K | 258.0K | ||
| Current liabilities | 2.26M | 2.34M | 1.90M | 2.44M | 2.37M | 1.95M | 878.0K | 2.35M | 1.29M | 3.20M |
| Long-term debt | 134.0K | 137.0K | 141.0K | 144.0K | 276.0K | 0 | 452.1K | 801.5K | ||
| Total debt | 137.0K | 140.0K | 144.0K | 147.0K | 580.0K | 50.0K | 452.1K | 829.2K | ||
| Total liabilities | 2.42M | 2.58M | 2.27M | 2.94M | 3.06M | 2.45M | 893.0K | 2.79M | 3.93M | 4.91M |
| Shareholders' equity | 6.33M | 7.32M | 14.9M | 23.9M | 32.8M | 26.5M | 33.6M | 8.06M | 7.36M | 13.5M |
| Shares outstanding | 80.9M | 66.7M | 53.1M | 51.1M | 47.8M | 39.3M | 39.5M | 30.8M | 28.3M | 23.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -4.79M | -5.20M | -7.05M | -7.46M | -10.8M | -8.68M | -3.33M | -1.93M | -1.39M | -157.7K |
| Capital spending | -112.0K | -138.0K | -310.0K | -236.0K | -1.47M | -4.39M | -15.0K | -136.0K | -145.7K | -122.2K |
| Free cash flow | -4.91M | -5.34M | -7.36M | -7.70M | -12.3M | -13.1M | -3.35M | -2.07M | -1.54M | -279.9K |
| Cash from investing | -442.0K | -317.0K | -235.0K | -742.0K | 3.39M | -9.55M | -260.0K | -657.0K | -241.4K | -183.4K |
| Cash from financing | 4.45M | 3.52M | 100.0K | 4.14M | 14.7M | -59.0K | 27.6M | 3.71M | 707.6K | 1.01M |
| Change in cash | -793.0K | -2.00M | -7.26M | -4.09M | 7.29M | -18.4M | 24.0M | 1.12M | -952.7K | 666.2K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Oct 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 21, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 13, 2026 | Current report | SEC |
| 8-K · Current report | Jul 6, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 8, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 20, 2026 | Material contract | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 30, 2026 | Current report | SEC |
| 10-KT · Transition report | Mar 18, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2026 | Material contract | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 5, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 2, 2026 | Current report | SEC |
| 8-K · Current report | Dec 15, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 8, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 4, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | Dec 3, 2025 | Offer document | SEC |
| S-3 · Registration statement | Nov 14, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Nov 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 10, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Oct 1, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 19, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Aug 18, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 18, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | Aug 4, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Jul 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 24, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 23, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 18, 2025 | Offer document | SEC |
| 10-K · Annual report | Jun 27, 2025 | Annual report | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| 5 · Annual statement of ownership | May 15, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | May 15, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | May 15, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | May 15, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 14, 2025 | Quarterly report | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 27, 2024 | Material contract | SEC |
| 8-K · Current report | Aug 26, 2024 | Meeting outcome | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 9, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | Aug 7, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 2, 2024 | Material contract | SEC |
| DEFA14A · Additional proxy material | Jul 9, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 8, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Jun 24, 2024 | Annual report | SEC |
| SC 13D · Big-stake notice | May 21, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 13, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 30, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 19, 2024 | Other filings | SEC |
| S-3 · Registration statement | Apr 17, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 5, 2024 | Current report | SEC |
| 8-K · Current report | Mar 27, 2024 | Material contract | SEC |
| 8-K · Current report | Mar 21, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Mar 21, 2024 | Offer document | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Mar 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2024 | Management or board change | SEC |
| 3 · Initial statement of ownership | Mar 12, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 14, 2024 | Quarterly report | SEC |
| 424B5 · Prospectus | Jan 31, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 4, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 4, 2024 | Other filings | SEC |
| S-3 · Registration statement | Dec 29, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 27, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Oct 27, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 6, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 4, 2023 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Oct 3, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Oct 3, 2023 | Other filings | SEC |
| S-3 · Registration statement | Sep 29, 2023 | Offer document | SEC |
| 8-K · Current report | Aug 21, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Jul 26, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Jul 7, 2023 | Annual report | SEC |
| 8-K · Current report | Jul 7, 2023 | Material contract | SEC |
| 8-K · Current report | Jul 6, 2023 | Material contract | SEC |
| NT 10-K · Late filing notice | Jun 30, 2023 | Explanation request | SEC |
| 4 · Change in ownership | Jun 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2023 | Insider trade | SEC |
| 5 · Annual statement of ownership | May 12, 2023 | Insider trade | SEC |
| 8-K · Current report | May 5, 2023 | Management or board change | SEC |
| 8-K · Current report | Mar 21, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Feb 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Dec 29, 2022 | Management or board change | SEC |
| 8-K · Current report | Dec 20, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Nov 1, 2022 | Quarterly report | SEC |
| 8-K · Current report | Sep 9, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 5, 2022 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Jul 25, 2022 | Meeting notice | SEC |
| 4 · Change in ownership | Jun 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2022 | Insider trade | SEC |
| 10-K · Annual report | Jun 22, 2022 | Annual report | SEC |
| 8-K · Current report | Jun 9, 2022 | Current report | SEC |
| 8-K · Current report | May 12, 2022 | Material contract | SEC |
| 8-K · Current report | Apr 18, 2022 | Current report | SEC |
| 8-K · Current report | Mar 23, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | Feb 10, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Jan 28, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 26, 2022 | Insider trade | SEC |
| 8-K · Current report | Jan 18, 2022 | Management or board change | SEC |
| 4 · Change in ownership | Dec 27, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2021 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Dec 22, 2021 | Offer document | SEC |
| 8-K · Current report | Dec 2, 2021 | Current report | SEC |
| 8-K · Current report | Nov 19, 2021 | Material contract | SEC |
| 10-Q · Quarterly report | Oct 29, 2021 | Quarterly report | SEC |
| 8-K · Current report | Oct 15, 2021 | Management or board change | SEC |
| 144 · Notice of proposed sale | Sep 17, 2021 | Other filings | SEC |
| DEF 14A · Proxy statement | Sep 15, 2021 | Meeting notice | SEC |
| 3/A · Initial statement of ownership, amended | Sep 15, 2021 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 15, 2021 | Insider trade | SEC |
| 5/A · Annual statement of ownership, amended | Sep 15, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 11, 2021 | Quarterly report | SEC |
| 10-K · Annual report | Jun 14, 2021 | Annual report | SEC |
| 3 · Initial statement of ownership | Jun 4, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2021 | Insider trade | SEC |
| 5 · Annual statement of ownership | May 17, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2021 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2021 | Other filings | SEC |
| 10-Q · Quarterly report | Feb 12, 2021 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Feb 1, 2021 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Jan 22, 2021 | Offer document | SEC |
| 8-K · Current report | Jan 13, 2021 | Management or board change | SEC |
| 424B5 · Prospectus | Jan 13, 2021 | Offer document | SEC |
| 8-K · Current report | Jan 13, 2021 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jan 5, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 31, 2020 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 31, 2020 | Other filings | SEC |
| S-3 · Registration statement | Dec 23, 2020 | Offer document | SEC |
| DEFA14A · Additional proxy material | Dec 21, 2020 | Meeting notice | SEC |
| 8-K · Current report | Dec 21, 2020 | Current report | SEC |
| DEF 14A · Proxy statement | Dec 8, 2020 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 4, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2020 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 30, 2020 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 20, 2020 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 13, 2020 | Explanation request | SEC |
| 8-K · Current report | Aug 20, 2020 | Current report | SEC |
| 10-Q · Quarterly report | Aug 19, 2020 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2020 | Explanation request | SEC |
| 8-K · Current report | Aug 11, 2020 | Current report | SEC |
| 8-K · Current report | Jul 17, 2020 | Current report | SEC |
| 10-K · Annual report | Jul 10, 2020 | Annual report | SEC |
| NT 10-K · Late filing notice | Jun 29, 2020 | Explanation request | SEC |
| 5/A · Annual statement of ownership, amended | Jun 15, 2020 | Insider trade | SEC |
| 5/A · Annual statement of ownership, amended | Jun 15, 2020 | Insider trade | SEC |
| 5/A · Annual statement of ownership, amended | Jun 15, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2020 | Insider trade | SEC |
| 5 · Annual statement of ownership | May 15, 2020 | Insider trade | SEC |
| 5 · Annual statement of ownership | May 15, 2020 | Insider trade | SEC |
| 5 · Annual statement of ownership | May 15, 2020 | Insider trade | SEC |
| 8-K · Current report | May 13, 2020 | Acquisition or disposal | SEC |
| 8-K · Current report | May 7, 2020 | Current report | SEC |
| 8-K · Current report | Mar 26, 2020 | Current report | SEC |
| 8-K · Current report | Mar 13, 2020 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 25, 2020 | Offer document | SEC |
| 10-Q · Quarterly report | Feb 10, 2020 | Quarterly report | SEC |
| 8-K · Current report | Jan 9, 2020 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Dec 13, 2019 | Meeting notice | SEC |
This page holds 200 of 818 filings. Open Filings
Cap table
Built by 6ix from IGC Pharma, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 116,687,169
- Fully diluted
- 116,687,169
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 116,687,169 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 116,687,169 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Richard Prins Other companies: Amphastar Pharmaceuticals, Inc. (Lead Independent Director · Since at least Aug 19, 2024) | Chairman · Since at least Mar 31, 2025 |
| Sudhakar V Shenoy Other companies: GTT Communications Inc (Director · Oct 15, 2006 – Apr 15, 2008 · Past) | Director · Mar 2, 2006 – Jun 11, 2019 · Past |
| Andres Sanchez | / Investor Relations · Since at least Oct 13, 2026 |
| Benysh Qureshi | Director of Operations · Since at least Nov 4, 2026 |
| Claudia Grimaldi | VP, CCO, PFO, & Director · Since at least Jun 11, 2019 |
| Jim Moran | Director · Since at least Jan 18, 2022 |
| Jose Ramos | Communications Manager · Since at least Nov 4, 2026 |
| Ram Mukunda | CEO & Director · Since at least Sep 29, 2026 |
| Terry Lierman | Director · Since at least Mar 12, 2024 |
Log in to ask 6ix AI your own questions about IGC Pharma, Inc.